Clinical trial
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
NCT00095459 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00095459 |
|---|---|
| Title | BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors |
| Official title | A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Bevacizumab, BAY 43-9006 |
| Enrollment | 57 |
| Start date | Nov 2, 2004 |
| Primary completion | Nov 1, 2005 |
| Completion | Jul 20, 2012 |
| First posted | Nov 5, 2004 |
| Last update posted | Dec 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: